Luye Pharma Approved to Start Japan Trials of Novel Anti-depressant

Luye Pays $5 Million Upfront for China Rights to PharmaMar's SCLC Treatment,绿叶制药获美国PharmaMar的SCLC治疗药物授权
Published on: August 23, 2019
Author: Amy Liu

Luye Pharma of Yantai has been approved to start Japan trials of its novel treatment for depression, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) in extended release tablet form. Ansofaxine Hydrochloride ER Tablets (LY03005) has already begun Phase III trials for LY03005 in China and the US. Luye expects LY03005 will avoid the side-effects of serotonin-only treatments for depression. The candidate is part of Luye’s larger effort to expand its portfolio of central nervous system drugs. Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science Medical Device Pharmaceutical